帕博西尼治疗脂肪肉瘤：来自土耳其肿瘤组（TOG）的真实世界多中心数据。

IF 1.8 4区医学 Q3 INFECTIOUS DISEASES

Journal of Chemotherapy Pub Date : 2025-09-10 DOI:10.1080/1120009X.2025.2557678

Fatih Kus, Hasan Cagri Yildirim, Dogan Bayram, Oznur Bal, Gokhan Sahin, Muzaffer Ugrakli, Atike Gokcen Demiray, Ozkan Alan, Ilgin Koc Kus, Firat Sirvan, Nilgun Yildirim, Olcun Umit Unal, Sendag Yaslikaya, Elif Sahin, Teoman Sakalar, Fatih Atalah, Ogur Karhan, Serkan Enki, Saadettin Kilickap, Serkan Akin

{"title":"帕博西尼治疗脂肪肉瘤：来自土耳其肿瘤组（TOG）的真实世界多中心数据。","authors":"Fatih Kus, Hasan Cagri Yildirim, Dogan Bayram, Oznur Bal, Gokhan Sahin, Muzaffer Ugrakli, Atike Gokcen Demiray, Ozkan Alan, Ilgin Koc Kus, Firat Sirvan, Nilgun Yildirim, Olcun Umit Unal, Sendag Yaslikaya, Elif Sahin, Teoman Sakalar, Fatih Atalah, Ogur Karhan, Serkan Enki, Saadettin Kilickap, Serkan Akin","doi":"10.1080/1120009X.2025.2557678","DOIUrl":null,"url":null,"abstract":"Background: Well-differentiated (WDLPS) and dedifferentiated liposarcomas (DDLPS) are subtypes with distinct behaviors, often driven by CDK4 amplification. While CDK4/6 inhibitors such as palbociclib show promise in trials, real-world data are scarce.Methods: We retrospectively analyzed 21 patients with advanced WDLPS or DDLPS treated with palbociclib monotherapy at 16 Turkish Oncology Group centers (2019-2022). Outcomes included progression-free survival (PFS), overall survival (OS), response, and safety.Results: Median age was 51 years; 38.1% had WDLPS and 61.9% DDLPS. Median PFS was 5.3 months and OS 9.1 months. The objective response rate was 0%, but disease control was achieved in 57.1%. WDLPS and earlier-line use were associated with numerically longer OS. Adverse events occurred in 71.4%, most often anemia (52.4%) and neutropenia (33.3%).Conclusion: Palbociclib showed modest activity with disease stabilization in some patients, highlighting the need for biomarker-driven and combination strategies.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG).\",\"authors\":\"Fatih Kus, Hasan Cagri Yildirim, Dogan Bayram, Oznur Bal, Gokhan Sahin, Muzaffer Ugrakli, Atike Gokcen Demiray, Ozkan Alan, Ilgin Koc Kus, Firat Sirvan, Nilgun Yildirim, Olcun Umit Unal, Sendag Yaslikaya, Elif Sahin, Teoman Sakalar, Fatih Atalah, Ogur Karhan, Serkan Enki, Saadettin Kilickap, Serkan Akin\",\"doi\":\"10.1080/1120009X.2025.2557678\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Well-differentiated (WDLPS) and dedifferentiated liposarcomas (DDLPS) are subtypes with distinct behaviors, often driven by CDK4 amplification. While CDK4/6 inhibitors such as palbociclib show promise in trials, real-world data are scarce.Methods: We retrospectively analyzed 21 patients with advanced WDLPS or DDLPS treated with palbociclib monotherapy at 16 Turkish Oncology Group centers (2019-2022). Outcomes included progression-free survival (PFS), overall survival (OS), response, and safety.Results: Median age was 51 years; 38.1% had WDLPS and 61.9% DDLPS. Median PFS was 5.3 months and OS 9.1 months. The objective response rate was 0%, but disease control was achieved in 57.1%. WDLPS and earlier-line use were associated with numerically longer OS. Adverse events occurred in 71.4%, most often anemia (52.4%) and neutropenia (33.3%).Conclusion: Palbociclib showed modest activity with disease stabilization in some patients, highlighting the need for biomarker-driven and combination strategies.\",\"PeriodicalId\":15338,\"journal\":{\"name\":\"Journal of Chemotherapy\",\"volume\":\" \",\"pages\":\"1-9\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1120009X.2025.2557678\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2557678","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

背景：高分化脂肪肉瘤（wdlp）和去分化脂肪肉瘤（DDLPS）是具有不同行为的亚型，通常由CDK4扩增驱动。尽管palbociclib等CDK4/6抑制剂在试验中显示出希望，但实际数据很少。方法：我们回顾性分析了16个土耳其肿瘤集团中心（2019-2022）接受帕博西尼单药治疗的21例晚期WDLPS或DDLPS患者。结果包括无进展生存期（PFS）、总生存期（OS）、反应和安全性。结果：中位年龄51岁；38.1%为WDLPS， 61.9%为ddlp。中位PFS为5.3个月，OS为9.1个月。客观有效率为0%，疾病控制率为57.1%。WDLPS和较早的行使用与较长的数字OS相关。不良事件发生率为71.4%，最常见的是贫血（52.4%）和中性粒细胞减少（33.3%）。结论：Palbociclib在一些患者中显示出适度的疾病稳定活性，突出了生物标志物驱动和联合策略的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG).

Background: Well-differentiated (WDLPS) and dedifferentiated liposarcomas (DDLPS) are subtypes with distinct behaviors, often driven by CDK4 amplification. While CDK4/6 inhibitors such as palbociclib show promise in trials, real-world data are scarce.

Methods: We retrospectively analyzed 21 patients with advanced WDLPS or DDLPS treated with palbociclib monotherapy at 16 Turkish Oncology Group centers (2019-2022). Outcomes included progression-free survival (PFS), overall survival (OS), response, and safety.

Results: Median age was 51 years; 38.1% had WDLPS and 61.9% DDLPS. Median PFS was 5.3 months and OS 9.1 months. The objective response rate was 0%, but disease control was achieved in 57.1%. WDLPS and earlier-line use were associated with numerically longer OS. Adverse events occurred in 71.4%, most often anemia (52.4%) and neutropenia (33.3%).

Conclusion: Palbociclib showed modest activity with disease stabilization in some patients, highlighting the need for biomarker-driven and combination strategies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Chemotherapy 医学-药学

CiteScore

3.70

自引率

0.00%

发文量

144

审稿时长

6-12 weeks

期刊介绍： The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy. The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs. Specific areas of focus include, but are not limited to: · Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents; · Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy; · Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents; · The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs; · Drug interactions in single or combined applications; · Drug resistance to antimicrobial and anticancer drugs; · Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research; · Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs; · Pharmacogenetics and pharmacogenomics; · Precision medicine in infectious disease therapy and in cancer therapy; · Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.